Related Experiment Video

Updated: Jun 3, 2026

Noninvasive Sampling of Mucosal Lining Fluid for the Quantification of In Vivo Upper Airway Immune-mediator Levels
05:31

Noninvasive Sampling of Mucosal Lining Fluid for the Quantification of In Vivo Upper Airway Immune-mediator Levels

Published on: August 7, 2017

[Expression of serum Clara cell secretory protein 10 in wheezing children under 5 years old]

Xiu-Fang Wang1, Ying-Ying Hou, Dan Bi

  • 1Department of Pediatrics, Third Affiliated Hospital of Zhengzhou University, Zhengzhou 450052, China. wxf456@126.com

Zhongguo Dang Dai Er Ke Za Zhi = Chinese Journal of Contemporary Pediatrics
|March 24, 2011
PubMed

Insights

Serum Clara cell secretory protein 10 (CC10) levels are lower in wheezing children, especially those with atopic risks. Lower CC10 correlates with higher IgE in atopic wheezing children.

Area of Science:

  • Pediatric Allergy and Immunology
  • Respiratory Medicine
  • Biochemistry

Context:

  • Recurrent wheezing in children under 5 is a significant clinical challenge.
  • Atopy is a known risk factor for persistent wheezing and asthma development.
  • Clara cell secretory protein 10 (CC10) is an anti-inflammatory protein produced in the airways.

Purpose:

  • To investigate the association between serum levels of Clara cell secretory protein 10 (CC10) and total IgE in young children experiencing recurrent wheezing.
  • To compare CC10 and IgE levels between wheezing children with and without high atopic risk, and a healthy control group.

Summary:

  • Serum CC10 levels were significantly lower in both wheezing groups compared to controls.
  • Wheezing children with high atopic risks exhibited lower CC10 levels than those without atopic risks.
  • Serum IgE levels were elevated in the atopic wheezing group compared to the non-atopic wheezing and control groups.
  • A strong negative correlation was observed between serum CC10 and IgE levels in wheezing children with atopic high risks.

Impact:

  • Findings suggest CC10 may play a protective role in pediatric wheezing, with diminished levels indicating increased susceptibility, particularly in atopic individuals.
  • The inverse relationship between CC10 and IgE in atopic wheezing children highlights potential biomarkers for disease severity and risk stratification.
  • This research contributes to understanding the pathophysiology of childhood wheezing and may inform future therapeutic strategies targeting CC10 or IgE pathways.
Abstract

More Related Videos

A Component-resolved Diagnostic Approach for a Study on Grass Pollen Allergens in Chinese Southerners with Allergic Rhinitis and/or Asthma06:34

A Component-resolved Diagnostic Approach for a Study on Grass Pollen Allergens in Chinese Southerners with Allergic Rhinitis and/or Asthma

Published on: June 4, 2017

Isolation and Quantitative Evaluation of Brush Cells from Mouse Tracheas10:25

Isolation and Quantitative Evaluation of Brush Cells from Mouse Tracheas

Published on: June 12, 2019

Related Concept Videos

Asthma III: Clinical Manifestations01:13

Asthma III: Clinical Manifestations

Asthma presents with a characteristic pattern of episodic respiratory symptoms that reflect underlying airway inflammation, bronchoconstriction, and mucus hypersecretion. Although severity varies among individuals, certain clinical manifestations are considered hallmarks of the disorder and often guide diagnosis and assessment.Respiratory SymptomsA persistent cough is one of the most common early features of asthma. It is frequently dry and tends to worsen at night or in the early morning,...
Respiratory Syncytial Virus Disease01:29

Respiratory Syncytial Virus Disease

Human respiratory syncytial virus (RSV) is a widespread pathogen that primarily targets infants and young children but also poses a serious health risk to elderly and immunocompromised individuals. Belonging to the Pneumoviridae family, RSV is a negative-sense, single-stranded RNA virus within the Pneumovirus genus. Its global health burden is significant, with millions of cases annually resulting in hospitalizations and mortality, particularly in resource-limited settings. Although most...
Asthma I: Introduction01:28

Asthma I: Introduction

Asthma is a chronic inflammatory disorder of the airways characterized by variable airflow obstruction and heightened bronchial responsiveness to a wide range of triggers. The underlying inflammation leads to airway swelling, mucus hypersecretion, and smooth muscle constriction, all of which narrow the airway lumen and impede airflow. Clinically, asthma presents with recurrent episodes of wheezing, shortness of breath, chest tightness, and coughing, symptoms that typically vary in intensity and...
Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs01:25

Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs

Asthma is a chronic respiratory condition for which new therapeutic avenues, including anti-inflammatory drugs like mast cell stabilizers and anti-IgE treatments, continue to be developed.
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
Chronic Obstructive Pulmonary Disease IV: Clinical Manifestations01:19

Chronic Obstructive Pulmonary Disease IV: Clinical Manifestations

Chronic Obstructive Pulmonary Disease, or COPD, is a long-term condition marked by persistent and only partially reversible airflow limitation. It involves two overlapping conditions—chronic bronchitis and emphysema—which often co-appear but differ in dominant symptoms and underlying mechanisms.Chronic Bronchitis FeaturesChronic bronchitis presents with a persistent productive cough and thick, sometimes purulent mucus due to airway inflammation, enlarged mucus glands, and goblet cell...
Asthma-IV: Diagnostic and Management01:30

Asthma-IV: Diagnostic and Management

The diagnosis and management of asthma are comprehensive, encompassing clinical assessments, lung function tests, and pharmacological interventions. Here's an overview:
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes: